Evidence map›Paper›PMID 37101125›Full record

SynthesisBMC infectious diseases2023

Epidemiology of clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) and its susceptibility to linezolid and vancomycin in Egypt: a systematic review with meta-analysis.

Ahmed Azzam, Heba Khaled, Maha Mosa, Neveen Refaey, Mohammed AlSaifi, Sarah Elsisi, Fatma Khaled Elagezy, May Mohsen

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Observational
  13. Article
  14. Article
  15. Observational
  16. Ceftaroline Exhibits PromisingInternational journal of microbiology · 2025
    Article
  17. Article
  18. Antimicrobial resistance inOne health (Amsterdam, Netherlands) · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Ahmed AzzamDepartment of Microbiology and Immunology, Faculty of Pharmacy, Helwan University, Cairo, Egypt. ahmed.abdelkareem@pharm.helwan.edu.eg.
Heba KhaledDepartment of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Maha MosaDepartment of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt.
Neveen RefaeyDepartment of Physical Therapy for Women's Health, Faculty of Physical Therapy, Cairo University, Cairo, Egypt.
Mohammed AlSaifiDepartment of Orthopedic and Trauma, Faculty of Medicine, 21 September University for Medicine and Applied Sciences, Sana, Yemen.
Sarah ElsisiDepartment of Clinical Pharmacy Surgery, Alexandria Main University Hospital, Alexandria, Egypt.
Fatma Khaled ElagezyDepartment of Biotechnology, Faculty of Fisheries and Aquaculture Sciences, Kafrelsheikh University, Kafr el-Sheikh, Egypt.
May MohsenFaculty of Medicine, Ain Shams University, Cairo, Egypt.
Cairo University · EGAin Shams University · EGAlexandria University · EGHelwan University · EGKafrelsheikh University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen that causes severe morbidity and mortality worldwide. For the establishment of national strategies to combat MRSA infection in each country, accurate and current statistics characterizing the epidemiology of MRSA are essential. The purpose of this study was to determine the prevalence of MRSA among Staphylococcus aureus clinical isolates in Egypt. In addition, we aimed to compare different diagnostic methods for MRSA and determine the pooled resistance rate of linezolid and vancomycin to MRSA. To address this knowledge gap, we conducted a systematic review with meta-analysis.

methodsA comprehensive literature search from inception to October 2022 of the following databases was performed: MEDLINE [PubMed], Scopus, Google Scholar, and Web of Science. The review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement. Based on the random effects model, results were reported as proportions with a 95% confidence interval (CI). Analyses of the subgroups were conducted. A sensitivity analysis was conducted to test the robustness of the results.

resultsA total of sixty-four (64) studies were included in the present meta-analysis, with a total sample size of 7171 subjects. The overall prevalence of MRSA was 63% [95% CI: 55-70]. Fifteen (15) studies used both PCR and cefoxitin disc diffusion for MRSA detection, with a pooled prevalence rate of 67% [95% CI: 54-79] and 67% [95% CI: 55-80], respectively. While nine (9) studies used both PCR and Oxacillin disc diffusion for MRSA detection, the pooled prevalences were 60% [95% CI: 45-75] and 64% [95% CI: 43-84], respectively. Furthermore, MRSA appeared to be less resistant to linezolid than vancomycin, with a pooled resistance rate of 5% [95% CI: 2-8] to linezolid and 9% [95% CI: 6-12] to vancomycin, respectively.

conclusionOur review highlights Egypt's high MRSA prevalence. The cefoxitin disc diffusion test results were found to be consistent with PCR identification of the mecA gene. A prohibition on antibiotic self-medication and efforts to educate healthcare workers and patients about the proper use of antimicrobials may be required to prevent further increases.

Indexed as

Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAnti-Bacterial AgentsBacterial ProteinsCefoxitinEgyptHumansLinezolidMicrobial Sensitivity TestsPenicillin-Binding ProteinsVancomycinAnti-Bacterial AgentsBacterial ProteinsCefoxitinLinezolidPenicillin-Binding ProteinsVancomycinCefoxitin disc diffusionEgyptEpidemiologyLinezolidMethicillin-resistant Staphylococcus aureusMRSAOxacillin disc diffusionPCRPrevalenceVancomycin

Identifiers

PMID37101125
PMCPMC10134521
OpenAlexW4367050591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.